164 related articles for article (PubMed ID: 24398956)
1. Targeting self-renewal, an Achilles' heel of cancer stem cells.
Wicha MS
Nat Med; 2014 Jan; 20(1):14-5. PubMed ID: 24398956
[No Abstract] [Full Text] [Related]
2. Colorectal cancer: targeting self-renewal of cancer stem cells in colorectal cancer-a future treatment option?
Leake I
Nat Rev Gastroenterol Hepatol; 2014 Feb; 11(2):75. PubMed ID: 24345889
[No Abstract] [Full Text] [Related]
3. Anticancer drugs: Curbing self-renewal of cancer-initiating cells.
Crunkhorn S
Nat Rev Drug Discov; 2014 Feb; 13(2):102. PubMed ID: 24481304
[No Abstract] [Full Text] [Related]
4. Self-renewal as a therapeutic target in human colorectal cancer.
Kreso A; van Galen P; Pedley NM; Lima-Fernandes E; Frelin C; Davis T; Cao L; Baiazitov R; Du W; Sydorenko N; Moon YC; Gibson L; Wang Y; Leung C; Iscove NN; Arrowsmith CH; Szentgyorgyi E; Gallinger S; Dick JE; O'Brien CA
Nat Med; 2014 Jan; 20(1):29-36. PubMed ID: 24292392
[TBL] [Abstract][Full Text] [Related]
5. Targeting of BMI-1 with PTC-209 inhibits glioblastoma development.
Kong Y; Ai C; Dong F; Xia X; Zhao X; Yang C; Kang C; Zhou Y; Zhao Q; Sun X; Wu X
Cell Cycle; 2018; 17(10):1199-1211. PubMed ID: 29886801
[TBL] [Abstract][Full Text] [Related]
6. Downregulation of Bmi1 in breast cancer stem cells suppresses tumor growth and proliferation.
Srinivasan M; Bharali DJ; Sudha T; Khedr M; Guest I; Sell S; Glinsky GV; Mousa SA
Oncotarget; 2017 Jun; 8(24):38731-38742. PubMed ID: 28418883
[TBL] [Abstract][Full Text] [Related]
7. The BMI1 inhibitor PTC-209 is a potential compound to halt cellular growth in biliary tract cancer cells.
Mayr C; Wagner A; Loeffelberger M; Bruckner D; Jakab M; Berr F; Di Fazio P; Ocker M; Neureiter D; Pichler M; Kiesslich T
Oncotarget; 2016 Jan; 7(1):745-58. PubMed ID: 26623561
[TBL] [Abstract][Full Text] [Related]
8. A miR-200c/141-BMI1 autoregulatory loop regulates oncogenic activity of BMI1 in cancer cells.
Dimri M; Kang M; Dimri GP
Oncotarget; 2016 Jun; 7(24):36220-36234. PubMed ID: 27105531
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of BMI1 induces autophagy-mediated necroptosis.
Dey A; Mustafi SB; Saha S; Kumar Dhar Dwivedi S; Mukherjee P; Bhattacharya R
Autophagy; 2016; 12(4):659-70. PubMed ID: 27050456
[TBL] [Abstract][Full Text] [Related]
10. Targeting of BMI-1 with PTC-209 shows potent anti-myeloma activity and impairs the tumour microenvironment.
Bolomsky A; Schlangen K; Schreiner W; Zojer N; Ludwig H
J Hematol Oncol; 2016 Mar; 9():17. PubMed ID: 26935956
[TBL] [Abstract][Full Text] [Related]
11. BMI1 is expressed in canine osteosarcoma and contributes to cell growth and chemotherapy resistance.
Shahi MH; York D; Gandour-Edwards R; Withers SS; Holt R; Rebhun RB
PLoS One; 2015; 10(6):e0131006. PubMed ID: 26110620
[TBL] [Abstract][Full Text] [Related]
12. BMI1 Inhibitors Down-regulate NOTCH Signaling and Suppress Proliferation of Acute Leukemia Cells.
Ohtaka M; Itoh M; Tohda S
Anticancer Res; 2017 Nov; 37(11):6047-6053. PubMed ID: 29061784
[TBL] [Abstract][Full Text] [Related]
13. Preclinical activity of the novel B-cell-specific Moloney murine leukemia virus integration site 1 inhibitor PTC-209 in acute myeloid leukemia: Implications for leukemia therapy.
Nishida Y; Maeda A; Chachad D; Ishizawa J; Qiu YH; Kornblau SM; Kimura S; Andreeff M; Kojima K
Cancer Sci; 2015 Dec; 106(12):1705-13. PubMed ID: 26450753
[TBL] [Abstract][Full Text] [Related]
14. Dysregulation of BMI1 and microRNA-16 collaborate to enhance an anti-apoptotic potential in the side population of refractory mantle cell lymphoma.
Teshima K; Nara M; Watanabe A; Ito M; Ikeda S; Hatano Y; Oshima K; Seto M; Sawada K; Tagawa H
Oncogene; 2014 Apr; 33(17):2191-203. PubMed ID: 23686310
[TBL] [Abstract][Full Text] [Related]
15. Nuclear Factor Erythroid-Derived 2-Like 2-Induced Reductive Stress Favors Self-Renewal of Breast Cancer Stem-Like Cells
Kim DH; Jang JH; Kwon OS; Cha HJ; Youn HJ; Chun KS; Surh YJ
Antioxid Redox Signal; 2020 Jun; 32(18):1313-1329. PubMed ID: 31672029
[No Abstract] [Full Text] [Related]
16. The Role of Castration-Resistant Bmi1+Sox2+ Cells in Driving Recurrence in Prostate Cancer.
Yoo YA; Vatapalli R; Lysy B; Mok H; Desouki MM; Abdulkadir SA
J Natl Cancer Inst; 2019 Mar; 111(3):311-321. PubMed ID: 30312426
[TBL] [Abstract][Full Text] [Related]
17. NSPc1 promotes cancer stem cell self-renewal by repressing the synthesis of all-trans retinoic acid via targeting RDH16 in malignant glioma.
Hu PS; Xia QS; Wu F; Li DK; Qi YJ; Hu Y; Wei ZZ; Li SS; Tian NY; Wei QF; Shen LJ; Yin B; Jiang T; Yuan JG; Qiang BQ; Han W; Peng XZ
Oncogene; 2017 Aug; 36(33):4706-4718. PubMed ID: 28394339
[TBL] [Abstract][Full Text] [Related]
18. Bmi1 inhibitor PTC-209 promotes Chemically-induced Direct Cardiac Reprogramming of cardiac fibroblasts into cardiomyocytes.
Testa G; Russo M; Di Benedetto G; Barbato M; Parisi S; Pirozzi F; Tocchetti CG; Abete P; Bonaduce D; Russo T; Passaro F
Sci Rep; 2020 Apr; 10(1):7129. PubMed ID: 32346096
[TBL] [Abstract][Full Text] [Related]
19. FoxG1 interacts with Bmi1 to regulate self-renewal and tumorigenicity of medulloblastoma stem cells.
Manoranjan B; Wang X; Hallett RM; Venugopal C; Mack SC; McFarlane N; Nolte SM; Scheinemann K; Gunnarsson T; Hassell JA; Taylor MD; Lee C; Triscott J; Foster CM; Dunham C; Hawkins C; Dunn SE; Singh SK
Stem Cells; 2013 Jul; 31(7):1266-77. PubMed ID: 23592496
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of USP2 eliminates cancer stem cells and enhances TNBC responsiveness to chemotherapy.
He J; Lee HJ; Saha S; Ruan D; Guo H; Chan CH
Cell Death Dis; 2019 Mar; 10(4):285. PubMed ID: 30918246
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
